Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.
2.

Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells.

Lai MW, Chen TC, Pang ST, Yeh CT.

Urol Oncol. 2012 Nov-Dec;30(6):871-8. doi: 10.1016/j.urolonc.2010.09.010. Epub 2011 Mar 10.

PMID:
21396835
3.

Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.

Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B, Lee SK.

Cancer Lett. 2010 Jan 28;287(2):196-206. doi: 10.1016/j.canlet.2009.06.011. Epub 2009 Jul 17.

PMID:
19616371
4.

Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma.

Yeh CT, Lu SC, Chen TC, Peng CY, Liaw YF.

Cancer Res. 2000 Sep 1;60(17):4697-700.

5.

Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.

Xing C, Xie H, Zhou L, Zhou W, Zhang W, Ding S, Wei B, Yu X, Su R, Zheng S.

Biochem Biophys Res Commun. 2012 Mar 30;420(1):29-35. doi: 10.1016/j.bbrc.2012.02.107. Epub 2012 Feb 27.

PMID:
22390936
6.

Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.

Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, Guo Z, Cheng T, Cao X.

Cancer Res. 2003 Dec 1;63(23):8323-9.

7.

Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant.

Yeh CT, Lu SC, Chao CH, Chao ML.

Biochem Biophys Res Commun. 2003 May 30;305(2):311-4.

PMID:
12745075
8.

KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway.

Li H, Jiang X, Yu Y, Huang W, Xing H, Agar NY, Yang HW, Yang B, Carroll RS, Johnson MD.

Oncogene. 2015 Mar 12;34(11):1432-41. doi: 10.1038/onc.2014.49. Epub 2014 Apr 7.

PMID:
24704824
9.

The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.

Chiu CY, Kuo KK, Kuo TL, Lee KT, Cheng KH.

Mol Cancer Res. 2012 Mar;10(3):415-27. doi: 10.1158/1541-7786.MCR-11-0293. Epub 2012 Jan 12.

10.

MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.

Wan C, Hou S, Ni R, Lv L, Ding Z, Huang X, Hang Q, He S, Wang Y, Cheng C, Gu XX, Xu G, Shen A.

Oncogene. 2015 Jan 8;34(2):237-45. doi: 10.1038/onc.2013.536. Epub 2013 Dec 16.

PMID:
24336329
11.

Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.

Mok WC, Wasser S, Tan T, Lim SG.

World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.

12.

RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.

Deng Q, Li KY, Chen H, Dai JH, Zhai YY, Wang Q, Li N, Wang YP, Han ZG.

Hepatology. 2014 Feb;59(2):518-30. doi: 10.1002/hep.26665. Epub 2013 Dec 18.

PMID:
23929653
13.

CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.

Dai W, Miao H, Fang S, Fang T, Chen N, Li M.

Mol Med Rep. 2016 Aug;14(2):1509-14. doi: 10.3892/mmr.2016.5410. Epub 2016 Jun 17.

14.

ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth.

Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M.

PLoS One. 2011 Mar 15;6(3):e17794. doi: 10.1371/journal.pone.0017794.

15.

Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.

Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Ryu JC, Park WS, Lee JY, Nam SW.

Int J Oncol. 2009 Dec;35(6):1257-64.

PMID:
19885547
16.

Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness.

Xu Y, Chen Q, Li W, Su X, Chen T, Liu Y, Zhao Y, Yu C.

Oncogene. 2010 Jun 10;29(23):3386-97. doi: 10.1038/onc.2010.90. Epub 2010 Mar 22.

PMID:
20305690
17.

P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma.

Fang ZP, Jiang BG, Gu XF, Zhao B, Ge RL, Zhang FB.

Acta Pharmacol Sin. 2014 Jan;35(1):82-8. doi: 10.1038/aps.2013.31. Epub 2013 May 20.

18.

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF.

Biochem Pharmacol. 2013 Feb 1;85(3):356-66. doi: 10.1016/j.bcp.2012.11.009. Epub 2012 Nov 23.

PMID:
23178652
19.

Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma.

Guo H, Lv Y, Tian T, Hu TH, Wang WJ, Sui X, Jiang L, Ruan ZP, Nan KJ.

Carcinogenesis. 2011 Dec;32(12):1897-904. doi: 10.1093/carcin/bgr220. Epub 2011 Oct 14.

PMID:
22002319

Supplemental Content

Support Center